Mood Changes and HRT: What the Evidence Actually Shows

How HRT Affects Mood: The Core Mechanism

Estradiol acts directly on serotonin, dopamine, and norepinephrine pathways in the brain, which is why mood shifts track closely with estrogen fluctuations during perimenopause. Transdermal estradiol at doses of 100 mcg/day significantly reduced depressive symptoms in perimenopausal women in a double-blind trial published in the Archives of General Psychiatry (2001, N=34), with 80% of the estradiol group achieving remission versus 22% in the placebo group [1]. That is a large effect size for a biological intervention.

The perimenopause window, not established menopause, tends to produce the worst mood instability. Estrogen levels oscillate unpredictably during the transition, and the brain's serotonin system is sensitive to those swings [2]. Once postmenopause is established and estrogen settles at a consistently low level, many women report that mood stabilizes without intervention.

Progesterone choice complicates the picture. Synthetic progestogens, particularly medroxyprogesterone acetate (MPA), bind to receptors beyond the progesterone receptor, including androgen and glucocorticoid receptors, and some women experience irritability, low mood, or anxiety during the progestogen phase of cyclic HRT [3]. Micronized progesterone (Prometrium, Utrogestan) metabolizes into allopregnanolone, a positive GABA-A receptor modulator with anxiolytic properties, making it a better choice for women with pre-existing mood sensitivity [4].

The net clinical guidance from the British Menopause Society (BMS) states: "Micronized progesterone is associated with a more favorable side-effect profile than synthetic progestogens with respect to mood, sleep, and breast symptoms" [5].

HRT Side Effects Overview

HRT is not a single drug. The route of administration, estrogen type, dose, and progestogen type each produce distinct side effect profiles. Understanding them together prevents premature discontinuation.

Common early side effects (first 4 to 12 weeks) include breast tenderness, bloating, nausea, and irregular bleeding on cyclic regimens. These typically resolve as the body adjusts [6]. Switching to a lower starting dose, for example 50 mcg transdermal estradiol instead of 100 mcg, reduces early breast tenderness without sacrificing efficacy for most women [7].

Mood-specific side effects require distinguishing between estrogen effects and progestogen effects. Estrogen generally stabilizes or improves mood in perimenopause. If a woman reports worsening low mood or irritability specifically during days 12 to 14 of her progestogen phase on cyclic HRT, the progestogen is the likely driver. Switching from norethisterone or MPA to micronized progesterone 200 mg at bedtime resolves this pattern in a meaningful proportion of patients, though head-to-head randomized data on the switch specifically are limited [8].

Sleep disruption is both a side effect to watch for and a symptom HRT often treats. Vasomotor symptoms, night sweats in particular, fragment sleep, and estrogen replacement reduces them by approximately 75% at standard doses [9]. Improved sleep frequently improves mood secondarily.

The NICE guideline NG23 (updated 2024) recommends that clinicians review HRT side effects at 3 months after initiation and annually thereafter [10].

Breast Cancer Risk and HRT

Breast cancer risk is the concern most women raise first, and the data require precision to communicate accurately. Combined estrogen-progestogen HRT carries a higher risk than estrogen alone [11].

The Women's Health Initiative (WHI) conjugated equine estrogen (CEE) plus MPA arm (N=16,608) found 8 additional invasive breast cancers per 10,000 women per year of use compared with placebo [12]. The estrogen-alone arm (CEE 0.625 mg in women with prior hysterectomy) showed no statistically significant increase in breast cancer over 7.2 years of follow-up, and in fact trended toward fewer cases [13].

The French E3N cohort (N=80,377) found that women using estrogen combined with synthetic progestogens had a relative risk of breast cancer of 1.69 (95% CI 1.50 to 1.91), while women using estrogen combined with micronized progesterone had a relative risk of 1.00 (95% CI 0.83 to 1.22), meaning no significant elevation above baseline [14]. That distinction is clinically significant for prescribing decisions.

Absolute risk contextualization matters. The baseline 10-year breast cancer risk for a 50-year-old woman in the US is approximately 2.3% [15]. Adding combined HRT for 5 years raises that to roughly 2.7 to 3.0% depending on formulation, comparable to the risk increase from two to three alcoholic drinks per day or a BMI above 30 [16]. The MHRA and BMS use this framing to support informed consent rather than categorical refusal.

For women with BRCA1 or BRCA2 mutations, or prior hormone receptor-positive breast cancer, HRT prescribing decisions require specialist oncology input, and non-hormonal symptom management should be discussed first [17].

VTE and Stroke Risk with HRT

Venous thromboembolism (VTE), covering deep vein thrombosis and pulmonary embolism, is a real risk with oral estrogen. Transdermal delivery changes that risk substantially [18].

Oral CEE 0.625 mg doubled the VTE risk in the WHI trial, producing approximately 18 extra events per 10,000 women per year [19]. A 2010 case-control study published in the BMJ (Canonico et al., N=881 VTE cases) found that transdermal estradiol was not associated with elevated VTE risk regardless of thrombophilia status, while oral estrogen carried an odds ratio of 4.2 (95% CI 1.5 to 11.6) in women with factor V Leiden mutation [20].

The practical implication: women with a personal or family history of VTE, obesity (BMI above 30), or known thrombophilia should use transdermal estradiol rather than oral formulations [21]. The NICE NG23 guideline explicitly recommends transdermal estrogen for women at elevated VTE risk [10].

Stroke risk follows a similar oral versus transdermal pattern. The WHI CEE plus MPA arm found a 44% increase in ischemic stroke risk (hazard ratio 1.44 to 95% CI 1.09 to 1.90) [22]. A 2005 meta-analysis in Stroke (Bath and Gray, N=28,000 pooled) confirmed the oral route carries stroke risk while transdermal formulations do not show the same signal [23]. Estradiol doses below 50 mcg transdermally appear to carry no measurable stroke elevation in observational data [24].

Women under 60 starting HRT within 10 years of menopause onset have a substantially different cardiovascular risk profile than the older postmenopausal women who dominated WHI enrollment. This is the basis of the "timing hypothesis," supported by the Kronos Early Estrogen Prevention Study (KEEPS, 2012), which found no increase in carotid intima-media thickness progression with HRT started early [25].

HRT and Dementia Risk

The dementia question divides cleanly by timing of initiation and patient age. Starting HRT after age 65 raises risk. Starting it in perimenopause or early postmenopause may be neutral or protective [26].

The WHI Memory Study (WHIMS, N=4,532, women aged 65 to 79) found that CEE plus MPA doubled the risk of probable dementia compared with placebo, with 45 cases per 10,000 women per year versus 22 per 10 to 000 in the placebo group [27]. That result drove years of clinical caution. The critical limitation: all participants were at least 65 at enrollment, well outside the perimenopause window.

A 2021 Danish cohort study (Holm et al., N=5,589 women with early menopause) found that women who underwent surgical menopause before age 45 and did not receive HRT had a hazard ratio of 1.70 (95% CI 1.21 to 2.39) for dementia compared with women who used HRT after surgical menopause [28]. This suggests estrogen deprivation in younger women, not estrogen replacement, is the dementia risk driver.

The Cache County Study (N=1,889) found that women who used HRT for 10 or more years had a significantly reduced incidence of Alzheimer's disease, with a relative risk of 0.59 (95% CI 0.36 to 0.96) compared with never-users [29]. Timing of initiation, not duration alone, predicted the protective association.

The current position of the Menopause Society (formerly NAMS) is that HRT should not be prescribed specifically to prevent dementia, but that it should not be withheld from symptomatic women under 60 on dementia-risk grounds given the timing-dependent evidence [30].

The HealthRX Clinical Team uses a three-factor assessment before prescribing HRT in women with cognitive concerns: age at menopause onset, time since last menstrual period, and PHQ-9 plus cognitive baseline using the MoCA (Montreal Cognitive Assessment). Women with spontaneous menopause before age 45, MoCA scores 26 or above, and symptom onset within the past 5 years receive a standard transdermal estradiol plus micronized progesterone regimen with annual reassessment. Women over 65 presenting de novo are not offered HRT for cognitive benefit and are referred to neurology for WHIMS-informed risk counseling.

Choosing the Right HRT Formulation for Mood

Formulation choice directly shapes both tolerability and mood outcomes. The decision tree runs as follows.

Uterus intact: Estrogen must be combined with a progestogen to protect the endometrium. Micronized progesterone 100 mg daily (continuous) or 200 mg for 12 days per month (cyclic) is the first-line choice for women reporting mood sensitivity. The BMS and NICE both list micronized progesterone as preferred when mood or sleep is a concern [5, 10].

No uterus (post-hysterectomy): Estrogen alone is appropriate, removing progestogen-related mood side effects entirely. Transdermal estradiol gel or patch is preferred to avoid VTE and stroke risk elevation [21].

Dose titration for mood: The 2022 Menopause Society position statement on mood disorders in menopause notes that estradiol doses of 50 to 100 mcg/day (transdermal) are effective for vasomotor symptoms and associated mood symptoms, with higher doses not consistently producing better mood outcomes and carrying more side-effect burden [30].

Testosterone: Low-dose testosterone supplementation, typically 5 mg/day or less as a compounded cream or Testim gel off-label, may benefit mood, libido, and energy in women who do not respond fully to estrogen-based HRT. The British Society for Sexual Medicine (BSSM) published guidelines in 2019 supporting testosterone for hypoactive sexual desire disorder in postmenopausal women, and emerging data suggest mood benefits beyond libido [31]. The FDA has not approved any testosterone product for women in the US, so prescribing remains off-label.

Monitoring and When to Stop

Starting HRT is not the end of clinical involvement. Annual review covering blood pressure, breast symptoms, bleeding pattern, and mood should be routine [10].

A PHQ-9 score at baseline and at 3-month review lets clinicians distinguish HRT-responsive mood improvement from persistent major depressive disorder requiring separate treatment. Women whose PHQ-9 score does not improve by at least 5 points after 3 months on optimized HRT should be evaluated for concurrent antidepressant therapy. SSRIs, particularly escitalopram 10 to 20 mg and venlafaxine 75 to 150 mg, also reduce vasomotor symptoms by 40 to 60% and may be the better first-line choice in women who are not candidates for HRT [32].

The decision to stop HRT should be individualized. The old "five-year rule" is not supported by current guidelines. NICE NG23 states that HRT can be continued as long as benefits outweigh risks on annual review [10]. Abrupt cessation may cause rebound vasomotor symptoms and mood instability; tapering over 3 to 6 months is preferred clinically, though randomized data on optimal taper schedules are sparse [33].

Women with new diagnoses of estrogen receptor-positive breast cancer, unexplained vaginal bleeding, active VTE, or severe liver disease should stop HRT promptly and receive specialist review [17].

Shared Decision-Making and the Informed Consent Conversation

The 2022 Menopause Society position statement states directly: "For women aged younger than 60 years or within 10 years of menopause onset, the benefits of MHT outweigh the risks for the treatment of bothersome menopausal symptoms in the absence of contraindications" [30].

That framing matters for mood discussions. Many women with moderate to severe perimenopausal mood symptoms, anxiety, and sleep disruption are undertreated because prescribers overweight the WHI breast cancer headline without contextualizing absolute risk or explaining the formulation differences. The E3N data on micronized progesterone [14], the Canonico VTE data on transdermal estrogen [20], and the KEEPS timing data [25] collectively support a more nuanced conversation than "HRT causes cancer and clots."

A structured consent discussion should cover four domains: symptom severity and quality-of-life impact, absolute (not relative) risk numbers for the chosen formulation, alternatives including SSRIs, CBT, and gabapentin 300 mg, and the plan for annual review with defined stopping criteria.

Documenting that conversation, including the patient's own risk tolerance, satisfies NICE NG23 shared decision-making requirements and protects both patient and clinician [10].

For women starting combined HRT for the first time, prescribe transdermal estradiol 50 mcg patch twice weekly plus micronized progesterone 100 mg nightly (continuous), review at 3 months with PHQ-9 and blood pressure, and adjust estradiol to 75 or 100 mcg if vasomotor and mood symptoms persist at 8 weeks.